Nasdaq Regulation



Eun Ah Choi

Senior Vice President
U.S. Listing Qualifications and Market Surveillance

March 16, 2023

Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549

Division of Corporation Finance:

This is to certify that on January 20, 2023, The Nasdaq Stock Market LLC (the "Exchange") received from YS Biopharma Co., Ltd. (the "Registrant") a copy of the Registrant's application on Form 8-A 12(b) for the registration of the following securities:

Ordinary Shares, \$0.00002 par value per share Warrants, each exercisable for one Ordinary Share

We further certify that the securities described above have been approved by the Exchange for listing and registration upon official notice of issuance.

We understand that the Registrant is seeking immediate acceleration of the effective date of registration, and we hereby join in such request.

Sincerely,

En Al Chri